Moreover, as activation of NF-κB has been linked to the resistance of ovarian cancer cells to PARP1 inhibitors (105), targeting this pathway could improve the outcome of the CDK12-PARP1 combination therapy. This evidence concerns the gene NFKB1 and ovarian cancer.